New methods for delivery of antifungal agents.

Amphotericin B remains the drug of choice for many invasive fungal infections. However, failures of therapy, relapses, and adverse effects are numerous. New modalities of antifungal therapy are extensively evaluated, including various preparations of liposomal amphotericin B and promising new agents such as itraconazole and fluconazole. Numerous studies indicate the potential benefit of liposomal amphotericin B. In particular, a dramatic decrease in the incidence of immediate adverse effects as compared with the incidence with amphotericin B complexed with deoxycholate has been documented. In addition, a prolonged in vitro antifungal activity has been observed with unilamellar liposomes. As yet there is no standardized commercially available preparation of liposomal amphotericin B. Extensive research in this field is in progress. Large comparative studies for the evaluation of the clinical efficacy of these preparations are planned. Intranasal administration of amphotericin B seems useful for the prevention of aspergillosis in predisposed patients. These various approaches should improve the management and prognosis of fungal infections.

[1]  J. Sculier,et al.  Amphotericin B Encapsulated in Liposomes Administered to Cancer Patients a , 1988, Annals of the New York Academy of Sciences.

[2]  Barriere Sl.  Infectious complications of AIDS. , 1988 .

[3]  R. Fromtling.  Overview of medically important antifungal azole derivatives , 1988, Clinical Microbiology Reviews.

[4]  J. Sculier,et al.  Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. , 1988, European journal of cancer & clinical oncology.

[5]  W. Byrne,et al.  Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B. , 1988, Annals of internal medicine.

[6]  R. Larson,et al.  Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. , 1988, The American journal of medicine.

[7]  M. Saag,et al.  Azole antifungal agents: emphasis on new triazoles , 1988, Antimicrobial Agents and Chemotherapy.

[8]  F. Meunier.  Fungal Infections in the Compromised Host , 1988 .

[9]  B. Dupont,et al.  Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. , 1988, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[10]  T. Shawker,et al.  Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. , 1988, Annals of internal medicine.

[11]  G. Lopez-Berestein,et al.  Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis , 1987, Antimicrobial Agents and Chemotherapy.

[12]  R L Juliano,et al.  Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections , 1987, Antimicrobial Agents and Chemotherapy.

[13]  J. Shenep,et al.  Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. , 1987, The Journal of infectious diseases.

[14]  B. Kramer,et al.  Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. , 1987, The American journal of medicine.

[15]  A. Matlow,et al.  Hepatic candidiasis: an increasing problem in immunocompromised patients. , 1987, The American journal of medicine.

[16]  G. Lopez-Berestein.  Liposomes as carriers of antimicrobial agents , 1987, Antimicrobial Agents and Chemotherapy.

[17]  F. Meunier.  Prevention of Mycoses in Immunocompromised Patients , 1987 .

[18]  L. Frankel,et al.  Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Elting,et al.  Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients , 1987, Antimicrobial Agents and Chemotherapy.

[20]  J. Gérain,et al.  Therapy of oropharyngeal candidiasis in cancer patients with fluconazole , 1987 .

[21]  J. Sculier,et al.  High-performance liquid chromatographic determination of amphotericin B in human serum. , 1987, Journal of chromatography.

[22]  A. Baert,et al.  Clinical Aspects of AIDS and AIDS-related Complex , 1986 .

[23]  M. Tarbit,et al.  Treatment of cryptococcal meningitis in mice with fluconazole. , 1986, The Journal of antimicrobial chemotherapy.

[24]  W. Fulkerson,et al.  Prevention of amphotericin B-induced rigors by dantrolene. , 1986, Archives of internal medicine.

[25]  J. Ruysschaert,et al.  Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Perfect,et al.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits , 1986, Antimicrobial Agents and Chemotherapy.

[27]  J. Graybill,et al.  Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858). , 1986, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[28]  P. Troke,et al.  Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice , 1985, Antimicrobial Agents and Chemotherapy.

[29]  M J Humphrey,et al.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans , 1985, Antimicrobial Agents and Chemotherapy.

[30]  B. Wong,et al.  Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. , 1985, Reviews of infectious diseases.

[31]  F. Szoka,et al.  Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys. , 1985, American journal of ophthalmology.

[32]  C. Alving,et al.  Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice , 1985, Antimicrobial Agents and Chemotherapy.

[33]  J. Graybill,et al.  Itraconazole treatment of murine aspergillosis. , 1985, Sabouraudia.

[34]  P. Troke,et al.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes , 1985, Antimicrobial Agents and Chemotherapy.

[35]  J. Reuben,et al.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. , 1985, The Journal of infectious diseases.

[36]  T. McQueen,et al.  Protective effect of liposomal-amphotericin B against C. albicans infection in mice. , 1985, Cancer Drug Delivery.

[37]  J. Gérain,et al.  Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia. , 1984, The New England journal of medicine.

[38]  C. Hawkins,et al.  Fungal infections in the immunocompromised host. , 1984, Clinics in haematology.

[39]  F. Szoka,et al.  Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice , 1984, Antimicrobial Agents and Chemotherapy.

[40]  A. Espinel-Ingroff,et al.  In vitro studies with R 51,211 (itraconazole) , 1984, Antimicrobial Agents and Chemotherapy.

[41]  F. Meunier-Carpentier.  Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections. , 1984, The American journal of medicine.

[42]  J. Gold.  Opportunistic fungal infections in patients with neoplastic disease. , 1984, The American journal of medicine.

[43]  B. Strom,et al.  Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. , 1984, Annals of internal medicine.

[44]  G. Lopez-Berestein,et al.  In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B , 1984, Antimicrobial Agents and Chemotherapy.

[45]  J. Ruysschaert,et al.  Iv administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man. , 1983, Cancer treatment reports.

[46]  E. Hersh,et al.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. , 1983, The Journal of infectious diseases.

[47]  J. Graybill,et al.  Amphotericin B in liposomes: a novel therapy for histoplasmosis. , 1982, The American review of respiratory disease.

[48]  J. Graybill,et al.  Treatment of murine cryptococcosis with liposome-associated amphotericin B. , 1982, The Journal of infectious diseases.

[49]  J. Aisner,et al.  Meperidine for the treatment of shaking chills and fever. , 1980, Archives of internal medicine.

[50]  J. Wingard,et al.  Candida tropicalis: a major pathogen in immunocompromised patients. , 1979, Annals of internal medicine.

[51]  J. Bennett,et al.  A pharmacologic guide to the clinical use of amphotericin B. , 1969, The Journal of infectious diseases.

[52]  D. Alling,et al.  Reducing amphotericin B reactions. A double-blind study. , 1963, The American review of respiratory disease.